NEW YORK & BRISBANE, Calif. –(BUSINESS WIRE)–Dec. 12, 2021– Pfizer Inc. (NYSE: PFE) and ย Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy
BRISBANE, Calif., April 1, 2019 /PRNewswire/ — Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will host a conference call on Tuesday, April 2 nd at 8:00 a.m. Eastern Time to provide a clinical development update.
โ Dosing of the first patient in the pivotal Phase 3 study anticipated in second half of 2020 โ NEW YORK & BRISBANE, Calif. –(BUSINESS WIRE)–Jun. 18, 2020– Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data
– First patient was dosed in pivotal Phase 3 AFFINE study in October 2020 NEW YORK & BRISBANE, Calif. –(BUSINESS WIRE)–Dec. 7, 2020– Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2
โ Conference call and webcast scheduled for 8:00 a.m. Eastern Time today BRISBANE, Calif. , April 2, 2019 /PRNewswire/ — Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced recent progress across its clinical portfolio, including early data for ST-400, an ex
Strong clinical momentum continues in Phase 1/2 STAAR study in Fabry disease with 20 patients dosed in total. Dosed third patient in cohort 1 of Phase 1/2 CAR-Treg STEADFAST study for TX200 in HLA A2 mismatched kidney transplantation. Unveiled Nav1.7 target to treat chronic neuropathic pain as
Announced additional progress towards strategic transformation into neurology-focused genomic medicine company. Focusing resources on proprietary epigenetic regulation therapies treating neurological diseases and novel AAV capsid delivery technologies.